Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO

Anebulo Pharmaceuticals, Inc.

Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.
Richie Cunningham appointed CEO and board member; previously CEO of Tyme Technologies and IXC Discovery.
Cunningham receives $450k base salary, time-vesting option for 600k shares (16 quarterly installments), and performance-based option for 140k shares.
Bimal Shah appointed to board and to Audit and Compensation Committees.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Simon Allen

Chief Executive Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-10-06
Successor: Richard (Richie) Anthony Cunningham
Filed: October 6, 2023, 7:59 PM ET

On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.

Appointed

Bimal Shah

Director

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-10-06
Filed: October 6, 2023, 7:59 PM ET

the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.

Appointed

Richard (Richie) Anthony Cunningham

Chief Executive Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-10-06
Filed: October 6, 2023, 7:59 PM ET

the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Allen departed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..

Action: terminated without cause
Role: Chief Executive Officer

Exact text from the filing

On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Bimal Shah was appointed as Director at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard (Richie) Anthony Cunningham was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.

View on SEC.gov

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-036500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.